Reports Monitor Global Biosimilar Market Estimates And Forecast

Bio-similar Market is expected to grow at a CAGR of 27.1% from 2017 to
2025, majorly due to the increasing patent expiration of the blockbuster
biologics
The " Global Biosimilar market, By Recombinant Products (Non-Glycosylated
Proteins, Glycosylated Proteins, peptides and others) By Application (Oncology, Blood
Disorders, Chronic and Auto-immune Disease, infectious diseases and others)
opportunities and forecast 2017-2025" report has been added to Reports Monitor's
database.
The study for Biosimilar Market will provide market size, estimates and forecast based on
the following years :
Historic data: 2015
Base Year Estimate: 2016
Forecast: 2017 to 2025
Biosimilars are the copied version of biologics that have undergone patent expiration.
The major factors that are driving the growth of the market includes
increasing
demand for these drugs due to rising geriatric population, their cost-effectiveness,
strategic collaborations ensuring enhanced throughput and clinical trial activities for
these drugs, and increasing support from the government and initiatives to develop and
promote these drugs.
Get a Free Sample of this Report @ https://www.reportsmonitor.com/request-
sample/?post=581161
Europe has around 27 biosimilar drugs available, US has been slower to hold on this
trend. Recently, the growth is accelerating due to patent expiration of popular biologics.
Also, it is expected that the rising acceptance of these drugs by governments and
physicians, and the growth of real-world evidence will help build patient confidence and
trust with regards to the efficacy and safety of these products. This, in turn will drive
growth in the market. Furthermore, as the price of these drugs is 30 to 50 per cent lower
than the originals, there exist huge potential healthcare cost savings, which will also
drive the market for these copied drugs. Currently, there are more of these drugs in
progress across the Asia-Pacific than anywhere else, leading to numerous great
opportunities. Producers of these drugs in Asian countries share various benefits over
their competitors in US and EU markets.